Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jul 20;25(29):5343-7.
doi: 10.1016/j.vaccine.2007.05.007. Epub 2007 May 25.

Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen

Gregory E D Mullen  1 , Joan A Aebig, Gelu Dobrescu, Kelly Rausch, Lynn Lambert, Carole A Long, Aaron P Miles, Allan Saul
Affiliations

Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen

Gregory E D Mullen et al. Vaccine. .

Abstract

CpG oligodeoxynucleotides are potent immunostimulants. In this study, CPG 7909 was formulated with the recombinant Plasmodium falciparum protein AMA1-C1 adsorbed to Alhydrogel (aluminum hydroxide) and used to immunize mice. Mice receiving free CPG 7909 in a separate same site injection to the AMA1-C1/Alhydrogel had the same antibody responses as mice receiving AMA1-C1/Alhydrogel alone. For mice immunized with CPG 7909 bound to the AMA1-C1/Alhydrogel formulation, there was a bell shaped CPG 7909 dose-response curve with the highest antibody response co-incident with the concentration of CPG 7909 that saturated binding to the Alhydrogel. At a higher CPG 7909 dose where 74% was unbound, there was no enhancement of response over AMA1-C1/Alhydrogel alone. Our results suggest that the adjuvant effects of CpGs are optimal when adsorbed to Alhydrogel and highlight the need for careful characterization of the vaccine formulation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Antibody responses in mice to AMA1-C1/Alhydrogel vaccines containing 30 ng AMA1-C1 and various amounts of unbound (A) or bound (B) CPG 7909 per dose. The formulation containing 50 μg of partially bound CpG (B) consisted of 26% and 35% bound CpG for the day 0 and 28 immunizations, respectively (determined by spectrophotometry). Arithmetic mean antibody in the groups of 9-10 mice were determined (bars). Individual mice are indicated as small circles.
Fig. 2
Fig. 2
IgG subclass determination in sera from selected groups of mice. AMA1-C1/Alhydrogel vaccines contained various amounts of unbound, partially bound or bound CPG 7909. Anti-AMA1-FVO-specific IgG1, IgG2a, IgG2b, and IgG3 levels were measured by ELISA using normalized sera and secondary antibody conjugates. Bars represent the arithmetic means of optical density readings of day 43 sera from groups of 9-10 mice with values for individual mice indicated with small circles.
See this image and copyright information in PMC

References

    1. Klinman DM, Currie D, Gursel I, Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev. 2004;199:201–16. - PubMed
    1. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374(6522):546–9. - PubMed
    1. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408(6813):740–5. - PubMed
    1. Tighe H, Takabayashi K, Schwartz D, et al. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol. 2000;30(7):1939–47. - PubMed
    1. Hartmann G, Weeratna RD, Ballas ZK, et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol. 2000;164(3):1617–24. - PubMed

Publication types